Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance.

Ferriss JS, Kim Y, Duska L, Birrer M, Levine DA, Moskaluk C, Theodorescu D, Lee JK.

PLoS One. 2012;7(2):e30550. doi: 10.1371/journal.pone.0030550.

2.

A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship.

Stordal B, Pavlakis N, Davey R.

Cancer Treat Rev. 2007 Dec;33(8):688-703. Review.

PMID:
17881133
3.

A systematic overview of chemotherapy effects in ovarian cancer.

Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care..

Acta Oncol. 2001;40(2-3):340-60. Review.

PMID:
11441940
4.

Medical therapy of advanced malignant epithelial tumours of the ovary.

Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.

Forum (Genova). 2000 Oct-Dec;10(4):323-32. Review.

PMID:
11535983
5.

Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.

Thigpen T, Vance R, Puneky L, Khansur T.

Gynecol Oncol. 1994 Dec;55(3 Pt 2):S97-107. Review.

PMID:
7835816
6.

Chemotherapy for advanced ovarian cancer. Advanced Ovarian Cancer Trialists Group.

Stewart L; Advanced Ovarian Cancer Trialists Group..

Cochrane Database Syst Rev. 2000;(2):CD001418. Review.

PMID:
10796788
7.

Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.

Chu Q, Vincent M, Logan D, Mackay JA, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care..

Lung Cancer. 2005 Dec;50(3):355-74. Review.

PMID:
16139391
8.

Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy.

Kurzeder C, Sauer G, Deissler H.

Curr Cancer Drug Targets. 2006 May;6(3):207-27. Review.

PMID:
16712458
9.

Platinum compounds in the treatment of advanced breast cancer.

Martín M.

Clin Breast Cancer. 2001 Oct;2(3):190-208; discussion 209. Review.

PMID:
11899413
10.

Management of platinum-sensitive recurrent ovarian cancer.

Pfisterer J, Ledermann JA.

Semin Oncol. 2006 Apr;33(2 Suppl 6):S12-6. Review.

PMID:
16716798
11.

Pharmaceutical management of ovarian cancer : current status.

Markman M.

Drugs. 2008;68(6):771-89. Review.

PMID:
18416585
12.

Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.

Ozols RF.

J Natl Compr Canc Netw. 2004 Sep;2 Suppl 2:S60-73. Review.

PMID:
19780247
13.

[Docetaxel and ovarian cancer].

Ray-Coquard I.

Bull Cancer. 2004 Feb;91(2):159-65. Review. French.

14.

Therapeutic strategies in epithelial ovarian cancer.

Kim A, Ueda Y, Naka T, Enomoto T.

J Exp Clin Cancer Res. 2012 Feb 13;31:14. doi: 10.1186/1756-9966-31-14. Review.

15.

The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer.

Vermorken JB.

Int J Gynecol Cancer. 2001;11 Suppl 1:21-30. Review.

PMID:
11488999
16.
17.

[Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].

du Bois A, Lück HJ, Meerpohl HG.

Zentralbl Gynakol. 1997;119(7):299-323. Review. German.

PMID:
9340970
18.

Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.

Muggia FM.

Semin Oncol. 2004 Dec;31(6 Suppl 14):17-24. Review.

PMID:
15726530
19.

What is the role of dose-dense therapy?

van der Burg ME, van der Gaast A, Vergote I, Burger CW, van Doorn HC, de Wit R, Stoter G, Verweij J.

Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:233-40. Review.

PMID:
16343238
20.

Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.

García-Sáenz JA, Custodio A, Casado A, Vidart JA, Coronado PJ, Martín M, López-Tarruella S, Puente J, Fernández C, Díaz-Rubio E.

Clin Transl Oncol. 2011 Feb;13(2):121-32. doi: 10.1007/s12094-011-0629-6. Review.

PMID:
21324801
Items per page

Supplemental Content

Support Center